XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), Cetrelimab (JNJ-63723283), Ersodetug (RZ358), MIPLYFFATM (arimoclomol), Acimtamig (AFM13), Ficlatuzumab (AV-299), COM902, Vosaroxin, Aldoxorubicin, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, DSUVIA (sufentanil sublingual tablet), IXINITY, Vidutolimod (CMP-001), MT-0169, RZ-402, G03-52-0, AFM24, Mezagitamab (TAK-079), among others.
Código da empresaXOMA
Nome da EmpresaXOMA Royalty Corp
Data de listagemJun 06, 1986
Fundado em2011
CEOMr. Owen P. Hughes, Jr.
Número de funcionários13
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 06
Endereço2200 Powell Street
CidadeEMERYVILLE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94608
Telefone15102047239
Sitehttps://www.xoma.com/
Código da empresaXOMA
Data de listagemJun 06, 1986
Fundado em2011
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados